• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ALDX

    Aldeyra Therapeutics Inc.

    Subscribe to $ALDX
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: aldeyra.com

    Peers

    $ACRS
    $APVO
    $ATXI
    $RLMD

    Recent Analyst Ratings for Aldeyra Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    4/3/2024$10.00Perform → Outperform
    Oppenheimer
    4/2/2024$10.00Buy
    H.C. Wainwright
    4/27/2022$15.00Buy
    H.C. Wainwright
    12/21/2021$25.00 → $21.00Buy
    Citigroup
    12/21/2021$24.00 → $15.00Outperform
    SVB Leerink
    See more ratings

    Aldeyra Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

      In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatment Arms, Potentially Address FDA Feedback following the Prior NDA Review New Drug Application Resubmission Is Anticipated Mid‑2025 A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be Submitted to the Planned NDA Resubmission as Supportive Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechno

      5/5/25 6:34:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Reproxalap Reproxalap is an investigational new drug candidate in development for the

      5/5/25 4:00:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the

      4/17/25 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

      Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were id

      4/3/25 8:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida. Dr. Brady's conversation with Marc Goodman, Senior Managing Director, Neuroscience, is scheduled to begin at 9:20 a.m. ET Monday, March 10, 2025. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast w

      3/10/25 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The conference is being conducted virtually on February 11, 2025. Dr. Brady's conversation with Francois Brisebois, Managing Director, Senior Biotech Research Analyst, is scheduled to begin at 9:20 a.m. ET Tuesday, February 11, 2025. To view the live webcast, log in to the Investors & Media section of the Aldeyra

      2/4/25 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in the Eyes Wide Open on Ophthalmology Panel at the Citi 2024 Global Healthcare Conference. The conference is being conducted in Miami, Florida December 2-5, 2024. Dr. Brady's participation in the Eyes Wide Open on Ophthalmology Panel is scheduled to begin at 1:45 p.m. ET on Thursday, December 5, 2024. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at htt

      12/2/24 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

      PDUFA Date is April 2, 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025. In conjunction with the acceptance of the NDA for review, Aldeyra announced the expansion of its exclusive option agreement with AbbVie Inc. (AbbVie). "Based on the FDA's acceptance of the NDA resubmission of reproxalap for dry eye disease for review, we

      11/18/24 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference 2024. The conference is being conducted in London, England November 19- 21, 2024. Dr. Brady's conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jefferies LLC., is scheduled to begin at 12:30 p.m. GMT Thursday, November 21, 2024. To view the live webcast, log in to the Investors & Media secti

      11/14/24 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024. Dr. Stryjewski will provide an overview of the Phase 2/3 clinical development of ADX-2191 in retinitis pigmentosa. The session will run from 3:30 – 5:30 p.m. ET on Friday, November 8, 2024. About Aldeyra Aldeyra Therapeutics is a biotechnology

      10/31/24 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aldeyra Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc.

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      11/14/24 4:50:29 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc. (Amendment)

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      2/14/24 4:52:01 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aldeyra Therapeutics Inc.

      SC 13G - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      2/13/24 4:58:48 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc. (Amendment)

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      10/18/23 6:07:25 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aldeyra Therapeutics Inc.

      SC 13G - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      10/4/23 3:22:13 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc. (Amendment)

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      2/14/23 2:33:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc. (Amendment)

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      2/3/23 11:25:52 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc. (Amendment)

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      2/14/22 3:45:54 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aldeyra Therapeutics Inc.

      SC 13G - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      2/9/22 4:57:05 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aldeyra Therapeutics, Inc. (Amendment)

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      1/4/22 9:44:44 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aldeyra Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Miller-Rich Nancy bought $10,447 worth of shares (922 units at $11.33) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      10/21/24 8:22:37 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $833,867 worth of shares (177,993 units at $4.68) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/8/24 5:32:55 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $1,934,505 worth of shares (504,272 units at $3.84) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/3/24 5:22:41 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aldeyra Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Clark William D

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/18/25 4:41:01 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Clark William D

      3 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/18/25 4:21:39 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Perceptive Advisors Llc sold $4,828,000 worth of shares (3,400,000 units at $1.42) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/7/25 6:43:07 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Brady Todd C

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      3/6/25 4:17:27 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Development Officer Machatha Stephen

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      3/6/25 4:13:41 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Miller-Rich Nancy bought $10,447 worth of shares (922 units at $11.33) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      10/21/24 8:22:37 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Alfieri Michael

      3 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      9/10/24 4:15:22 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Machatha Stephen sold $75,975 worth of shares (16,041 units at $4.74), decreasing direct ownership by 6% to 236,771 units (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      8/14/24 4:24:22 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Greenberg Bruce sold $51,313 worth of shares (10,834 units at $4.74), decreasing direct ownership by 8% to 126,382 units (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      8/14/24 4:24:15 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Douglas Richard

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      6/6/24 4:15:15 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aldeyra Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aldeyra Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Aldeyra Therapeutics from Perform to Outperform and set a new price target of $10.00

      4/3/24 7:39:55 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on Aldeyra Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $10.00

      4/2/24 8:09:59 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on Aldeyra Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $15.00

      4/27/22 7:14:02 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Aldeyra Therapeutics with a new price target

      Citigroup reiterated coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $21.00 from $25.00 previously

      12/21/21 9:39:53 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Aldeyra Therapeutics with a new price target

      SVB Leerink reiterated coverage of Aldeyra Therapeutics with a rating of Outperform and set a new price target of $15.00 from $24.00 previously

      12/21/21 5:24:06 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Aldeyra Therapeutics

      SVB Leerink initiated coverage of Aldeyra Therapeutics with a rating of Outperform

      3/12/21 7:32:01 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Aldeyra Therapeutics with a new price target

      SVB Leerink initiated coverage of Aldeyra Therapeutics with a rating of Outperform and set a new price target of $22.00

      3/12/21 6:14:06 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Aldeyra Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $26.00

      2/8/21 6:20:02 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aldeyra Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the

      4/17/25 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aldeyra Therapeutics Inc. SEC Filings

    See more
    • Aldeyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      5/6/25 7:01:18 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Aldeyra Therapeutics Inc.

      DEFA14A - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      4/25/25 4:25:44 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aldeyra Therapeutics Inc.

      DEF 14A - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      4/25/25 4:19:43 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      4/17/25 4:01:40 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.

      SCHEDULE 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      4/7/25 6:52:21 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure

      8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      4/3/25 4:50:12 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Aldeyra Therapeutics Inc.

      10-K/A - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      3/28/25 5:19:15 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Aldeyra Therapeutics Inc.

      S-8 - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      2/28/25 5:03:31 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Aldeyra Therapeutics Inc.

      10-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      2/28/25 4:36:59 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      11/18/24 7:01:10 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aldeyra Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

      In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatment Arms, Potentially Address FDA Feedback following the Prior NDA Review New Drug Application Resubmission Is Anticipated Mid‑2025 A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be Submitted to the Planned NDA Resubmission as Supportive Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechno

      5/5/25 6:34:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Reproxalap Reproxalap is an investigational new drug candidate in development for the

      5/5/25 4:00:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

      Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were id

      4/3/25 8:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

      New Drug Application Resubmission Anticipated in 2024 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort (P=0.004), a U.S. Food and Drug Administration (FDA)-accepted symptom of dry e

      8/8/24 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the Phase 3 dry eye disease clinical trial of reproxalap. The dial-in numbers are (888) 596-4144 for domestic callers and (646) 968-2525 for international callers. The access code is 7321123. A live audio webcast of the conference call also will be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to di

      8/7/24 4:01:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable resubmission of a New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA). Following discussions with the FDA, Aldeyra intends to initiate a dry eye chamber clinical trial in the first half of 2024. Contingent on positive results from the planned clinical trial, NDA resubmission is expected in the second half of 2

      3/28/24 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

      Conference Call and Webcast at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. "2023 was a transformative year for Ligand, both operationally and financially. We refocused the company to be a lean-infrastructure, high-margin business," said Todd Davis, CEO of Ligand. "We enhanced our deal making capabilities with the strengthening of our senior team and opening of

      2/27/24 7:00:00 AM ET
      $ALDX
      $LGND
      $MRK
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis

      Statistically significant improvement from baseline observed in investigator-assessed Eczema Area and Severity Index (EASI, p=0.0006) and Investigator Global Assessment (IGA, p<0.0001) EASI 75% improvement (EASI-75) threshold observed in three patients (38%), and affected body surface area was completely cleared in one patient (13%) Patient-reported itching eliminated in two patients (25%) and clinically relevant threshold achieved in patient-reported eczema score (POEM) in six patients (75%) Statistically significant improvement from baseline observed in Hamilton Rating Scale for Depression (HAM-D, p=0.02) Results supportive of advancing ADX-246, an analog investigational drug

      12/19/23 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis. The dial-in numbers are (888) 415-4305 for domestic callers and (646) 960-0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Aldeyra Aldeyra Therapeutics is a biotechnology compa

      12/18/23 4:01:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

      Additional Trial Required to Demonstrate Positive Effect on the Treatment of Ocular Symptoms in Dry Eye Disease Special Protocol Assessment Submitted on November 16, 2023 for Dry Eye Disease Chamber Crossover Clinical Trial Proposed Trial Top-Line Results and Potential NDA Resubmission Anticipated in First Half of 2024 Cash Runway Extended into Late 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxala

      11/27/23 4:07:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care